GlassScriptPhysician profile
Andrew J Kerwin
NPI 1033184270
$692.27
in general payments reported to CMS, 2019-2025
16 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Surgical Critical Care provider received nationally (typical 2025 total: $234).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $59.36 · 2023: $227 · 2024: $118 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $145.83 | 2023 | Advantagerib |
| Ethicon US, LLC | $118.78 | 2024-2025 | Vistaseal, Enseal |
| Haemonetics Corporation | $112.99 | 2025 | Teg6s Hemostasis System |
| Baxter Healthcare | $79.21 | 2022-2023 | Perclot |
| Smith+Nephew, INC. | $66.57 | 2024-2025 | Oasis, Grafix Pl, Oasis Micro |
| Atricure, INC. | $34.16 | 2024-2025 | Atricure Cryoice Cryosphere Cryoablation System |
| Acera Surgical, INC. | $31.85 | 2024 | Restrata Wound Matrix |
| Masimo Corporation | $21.36 | 2024 | Set and Rainbow Set |
| Integra Lifesciences Corporation | $21.11 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Teleflex LLC | $20.46 | 2023 | Quikclot |
| La Jolla Pharmaceutical Company | $20.44 | 2025 | Giapreza |
| Kci USA, INC. | $19.51 | 2023 | V.A.C. Veraflo, Prevena |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Kerwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.